DEMENTIA
SCIENTISTS in Scotland have found a potential cure for the most common cause of dementia and strokes in old people – using cheap, everyday drugs.
Human trials are already being carried out after rats were treated with a combination of cilostazol and isosorbide mononitrate.
Researchers say once trials are complete they could be available to patients within two years.
The breakthrough comes days after new figures showed Scotland is facing a dementia “timebomb” as experts warn conditions such as Alzheimer’s will soon overtake heart disease as the biggest killer.
The drugs involved in the latest study repaired the deterioration of blood vessels in rats’ brains associated with a condition called cerebral small vessel disease, or SVD, and reversed the symptoms.
SVD is responsible for almost half of all dementia cases in the UK and accounts for one in five strokes. It can also aggravate the symptoms of Alzheimer’s disease.
Professor Anna Williams, group leader at Edinburgh University’s Medical Research Council (MRC) Centre for Regenerative Medicine, said: “We are very excited because it is the first time we have really got to the bottom of why this disease called cerebral small vessel disease happens.
“We gave rats some drugs that made the cells happier and managed to reverse the changes in the brain. We have found a way to reverse it. That is exciting for people with dementia.”
Professor Williams added: “The nice things about these drugs is that they are already tested on people, they are cheap and readily available so can quickly be given to people.”
Cilostazol and isosorbide mononitrate are commonly used by patients with heart and blood pressure ailments. Pills are available for around 60p and 20p respectively.
The research team discovered that SVD occurs when cells that line the small blood vessels in the brain become dysfunctional. This causes them to secrete a molecule into the brain, which stops production of myelin, a protective layer that surrounds brain cells, leading to brain damage. The drugs prevent this.
Experts hailed the breakthrough. A spokesperson for the charity Age Scotland, said: “Any development of this nature and any measures to combat dementia is good news indeed.”
The research, first published in Science Translational Medicine, was carried out at the MRC centre and the UK Dementia Research Institute at Edinburgh University. It was funded by the MRC, Alzheimer’s Research UK and the private Leducq Foundation, based in Paris.
Dr Sara Imarisio, head of research at Alzheimer’s Research UK, said: “The findings highlight a promising direction for research into treatments that could limit the damaging effects of blood vessel changes and help keep nerve cells functioning for longer.”
Researchers say further studies will be needed to test whether the treatment also works once the disease is firmly established, but trials will be over within a year.
Estimates indicate there are almost 47 million people living with dementia worldwide and the numbers affected are expected to double every 20 years, rising to more than 115 million by 2050.